Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026
Rhea-AI Summary
Achieve Life Sciences (Nasdaq: ACHV) will report fourth quarter and full year 2025 financial results and provide a corporate update on its cytisinicline development program on March 24, 2026 at 8:30 AM EDT.
Investors can access a live webcast, join the conference call (877-269-7756 U.S. & Canada; 201-689-7817 International; conference ID 13758715), and view a replay posted about three hours after the call that will be archived for 90 days.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ACHV is up 0.72% while several biotech peers (ACOG, ELDN, MIST, NVCT) show mixed to negative moves and CHRS is flat, pointing to stock-specific positioning rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Clinical data update | Positive | +5.8% | Pooled Phase 3 cytisinicline data and ORCA-OL experience presented at SRNT. |
| Jan 30 | Inducement option grants | Neutral | +2.9% | New-hire stock options totaling 115,000 shares under 2024 Equity Inducement Plan. |
| Jan 12 | Executive promotion | Positive | +1.8% | Promotion of Dr. Mark Rubinstein to Chief Medical Officer amid progress on milestones. |
| Dec 17 | Investor meetings | Positive | +2.6% | Planned one-on-one meetings during J.P. Morgan Healthcare Conference week. |
| Dec 08 | Inducement option grants | Neutral | -0.2% | Inducement stock options for new hires including Chief Legal Officer. |
Recent company news—mainly clinical data, management updates, and investor outreach—has generally coincided with modest positive price reactions, with only a small divergence around option-related announcements.
Over the last several months, ACHV has highlighted progress around its cytisinicline program and corporate development. A data update at SRNT on Mar 4, 2026 saw a 5.77% gain, while management and board-related items such as inducement awards and executive promotions in Jan 2026 also drew small positive reactions. Investor-focused activities like meetings around the J.P. Morgan conference in Dec 2025 were met with a 2.6% rise. Against this backdrop, today’s simple earnings date announcement fits a pattern of steady communication rather than a major new catalyst.
Regulatory & Risk Context
An effective Form S-3 filed on 2026-01-23 registers up to $300,000,000 of various securities, which may be issued in future offerings with proceeds available for general corporate purposes such as R&D, commercialization, working capital, debt reduction, acquisitions, and capital expenditures.
Market Pulse Summary
This announcement sets the timing for fourth quarter and full year 2025 results and a program update on March 24, 2026, without adding new financial or clinical details. Historically, ACHV’s communications—data presentations, management changes, and investor events—have produced modestly positive moves. Investors may watch how upcoming results intersect with the existing Form S-3 for up to $300,000,000 of securities and prior executive option grants when assessing capital needs and dilution risk.
AI-generated analysis. Not financial advice.
SEATTLE and VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its fourth quarter and full year 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday, March 24, 2026, at 8:30 AM EDT.
To access the webcast, please use the following link: 4Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and referencing conference ID 13758715. A webcast replay will be available approximately three hours after the call and archived on the website for 90 days.
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. In September 2025, the company announced that its New Drug Application, submitted to the U.S. Food and Drug Administration (FDA) in June 2025, had been accepted for review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026. The NDA is for cytisinicline to be used as a treatment of nicotine dependence for smoking cessation in adults, based on two successfully completed Phase 3 studies and its open-label safety study. Additionally, the company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication.
About Cytisinicline
There are approximately 25 million adults in the United States who smoke combustible cigarettes.1 Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.2,3 More than
In addition, there are nearly 18 million adults in the United States who use e-cigarettes, also known as vaping.1 In 2024, approximately 1.6 million middle and high school students in the United States reported using e-cigarettes.4 There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. FDA has awarded the Commissioner’s National Priority Voucher for e-cigarette or vaping cessation and granted Breakthrough Therapy designation to address this critical need.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products. Cytisinicline is an investigational product candidate being developed as a treatment of nicotine dependence for smoking cessation and has not been approved by the FDA for any indication in the United States.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements Achieve makes regarding the timing and nature of cytisinicline clinical development and regulatory review and approval, data results and commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the development and effectiveness of new treatments, and the successful commercialization of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Achieve Contact
Nicole Jones
VP, Strategic Communications and Stakeholder Relations
ir@achievelifesciences.com
425-686-1510
References
1National Center for Health Statistics. National Health Interview Survey, 2023 and 2024. 2026 (https://www.cdc.gov/nchs/nhis.htm).
2World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.
3U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.
4Jamal A, Park-Lee E, Birdsey J, et al. Tobacco Product Use Among Middle and High School Students — National Youth Tobacco Survey, United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:917–924.
FAQ
When will Achieve Life Sciences (ACHV) report Q4 and full year 2025 results?
How can investors access the Achieve Life Sciences (ACHV) March 24, 2026 webcast?
What are the dial-in details for Achieve Life Sciences (ACHV) conference call on March 24, 2026?
Will the Achieve Life Sciences (ACHV) webcast include an update on cytisinicline?
When will the replay of the Achieve Life Sciences (ACHV) earnings call be available and for how long?
Can international investors join the Achieve Life Sciences (ACHV) March 24, 2026 earnings call?
